1. BRIGATINIB SHOWS PRECLINICAL PROMISE FOR AGGRESSIVE RELAPSED/REFRACTORY AK = LK-POSITIVE ALCL. (October 2022) Authors: Matthews, J.; Prokoph, N.; Trigg, R.; Montes-Mojarro, I.; Fend, F.; Kenner, L.; Geoerger, B.; Johnston, R.; Murray, M.; Brugières, L.; Burke, A.; Turner, Suzanne D Journal: Leukemia research Issue: Volume 121(2022)Supplement Page Start: S16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase 1 study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK): Safety, pharmacokinetics and efficacy results from the fed population. (December 2016) Authors: Fischer, M.; Wulff, B.; Baruchel, S.; Berlanga, P.; Trahair, T.; Mechinaud, F.; Schulte, J.; Modak, S.; Merks, J.H.; Zwaan, C.M.; Marshall, L.V.; Casanova, M.; Branle, F.; Malet, I.; Emeremni, A.C.; Geoerger, B. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗